| __timestamp | Alnylam Pharmaceuticals, Inc. | Evotec SE |
|---|---|---|
| Wednesday, January 1, 2014 | 190249000 | 12404000 |
| Thursday, January 1, 2015 | 276495000 | 18343000 |
| Friday, January 1, 2016 | 382392000 | 18108000 |
| Sunday, January 1, 2017 | 390635000 | 17614000 |
| Monday, January 1, 2018 | 505420000 | 35619000 |
| Tuesday, January 1, 2019 | 655114000 | 58432000 |
| Wednesday, January 1, 2020 | 654819000 | 63945000 |
| Friday, January 1, 2021 | 792156000 | 72200000 |
| Saturday, January 1, 2022 | 883015000 | 76642000 |
| Sunday, January 1, 2023 | 1004415000 | 57519000 |
| Monday, January 1, 2024 | 1126232000 |
Unleashing the power of data
In the competitive landscape of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Alnylam Pharmaceuticals, Inc. has consistently outpaced Evotec SE in R&D investment. From 2014 to 2023, Alnylam's R&D expenses surged by over 400%, peaking at approximately $1 billion in 2023. This reflects a strategic focus on pioneering RNA interference therapeutics. In contrast, Evotec SE's R&D spending grew by about 360% during the same period, reaching nearly $58 million in 2023. This disparity highlights Alnylam's aggressive investment strategy, which is nearly 17 times that of Evotec in 2023. Such financial commitment underscores Alnylam's ambition to lead in the biotech sector, while Evotec's steady growth indicates a more measured approach. As the industry evolves, these spending patterns may shape the future of medical breakthroughs.
Research and Development Investment: Merck & Co., Inc. vs Evotec SE
Research and Development: Comparing Key Metrics for Gilead Sciences, Inc. and Alnylam Pharmaceuticals, Inc.
GSK plc vs Alnylam Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and Sarepta Therapeutics, Inc.
Alnylam Pharmaceuticals, Inc. vs Madrigal Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Research and Development Investment: Alnylam Pharmaceuticals, Inc. vs Amicus Therapeutics, Inc.
Who Prioritizes Innovation? R&D Spending Compared for Alnylam Pharmaceuticals, Inc. and Galapagos NV
Research and Development: Comparing Key Metrics for Catalyst Pharmaceuticals, Inc. and Evotec SE
R&D Spending Showdown: HUTCHMED (China) Limited vs Evotec SE
Research and Development Investment: Protagonist Therapeutics, Inc. vs Evotec SE
Comparing Innovation Spending: Ligand Pharmaceuticals Incorporated and Evotec SE
R&D Spending Showdown: Evotec SE vs Xencor, Inc.